Shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) rose 4.7% during mid-day trading on Wednesday . The company traded as high as $7.18 and last traded at $6.84, with a volume of 1,854,571 shares traded. The stock had previously closed at $6.53.

RPTP has been the topic of a number of research analyst reports. Wedbush reissued a “neutral” rating and issued a $4.00 price target on shares of Raptor Pharmaceutical Corp. in a research note on Friday, May 6th. Zacks Investment Research raised Raptor Pharmaceutical Corp. from a “hold” rating to a “buy” rating and set a $7.50 price objective on the stock in a research note on Thursday, August 11th. Citigroup Inc. lowered Raptor Pharmaceutical Corp. from a “buy” rating to a “neutral” rating and lifted their price objective for the company from $6.00 to $8.00 in a research note on Monday, August 8th. Finally, FBR & Co reaffirmed a “hold” rating on shares of Raptor Pharmaceutical Corp. in a research note on Sunday, June 12th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Raptor Pharmaceutical Corp. currently has an average rating of “Hold” and an average target price of $7.21.

The company’s market cap is $638.94 million. The company’s 50 day moving average is $6.16 and its 200 day moving average is $5.06.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last announced its earnings results on Thursday, August 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. The company had revenue of $32.05 million for the quarter, compared to analyst estimates of $28.52 million. The firm’s revenue for the quarter was up 37.4% on a year-over-year basis. During the same period last year, the firm earned ($0.17) earnings per share. Analysts predict that Raptor Pharmaceutical Corp. will post ($0.90) earnings per share for the current year.

An institutional investor recently raised its position in Raptor Pharmaceutical Corp. stock. Cornerstone Capital Management Holdings LLC. raised its stake in shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) by 319.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 251,803 shares of the company’s stock after buying an additional 191,703 shares during the period. Cornerstone Capital Management Holdings LLC. owned about 0.30% of Raptor Pharmaceutical Corp. worth $1,310,000 as of its most recent SEC filing.

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.